<DOC>
	<DOCNO>NCT02445222</DOCNO>
	<brief_summary>Per Health Authorities guideline gene therapy medicinal product utilize integrating vector ( e.g . lentiviral vector ) , long term safety efficacy follow treat patient require . The purpose study monitor patient expose CD19 direct CAR T-cells ( CD19 CART ) 15 year follow last CD19 CART ( e.g . CTL019 ) infusion ass risk delay adverse event ( AEs ) , monitor replication competent lentivirus ( RCL ) ass long-term efficacy , include vector persistence .</brief_summary>
	<brief_title>CD19 CART Long Term Follow Up ( LTFU ) Study</brief_title>
	<detailed_description>Patients enrol follow completion early discontinuation Novartis sponsor support study CD19 direct CAR T-Cell treatment follow 15 year post treatment last CD19 direct CAR T-Cell treatment . Patients monitor safety efficacy within primary treatment protocol protocol define duration . While every effort make keep patient follow-up within respective treatment protocol , patient drop treatment protocols time . Patients discontinue primary treatment protocol reason enrol long term follow ( LTFU ) . This allow collect data long term safety efficacy ( applicable ) mandate health authority patient treat CD19 CART therapy within concept single protocol . Collection long term effect CD19 CART cell therapy help define risk-benefit profile CD19 CART .</detailed_description>
	<criteria>All patient receive antiCD19 direct CART therapy complete discontinue early Novartis sponsor treatment protocol utilized CD19directed CART cell CD19 CART trial sponsor University Pennsylvania Novartis contractual agreement codevelop CAR technology . Patients provide informed consent long term follow study prior study participation . There specific exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>